Pfizer's stock has fallen close to 30% over the past five years, but the company is still leaning on a deep pipeline and a string of expensive bets to argue that the story is not finished. The shares trade at just nine times expected future profits, a level that reflects how wary investors have become about pfe stock.
The pressure comes from a real place. Pfizer faces patent cliffs for Eliquis, Ibrance, Xtandi, Xeljanz and other products, and Albert Bourla said in 2022 that the company might lose up to $18 billion in revenue from 2025 through 2030. He also said Pfizer was planning to bolster the company's top line by as much as $25 billion, a target that now hangs over every earnings call and drug launch.
That backdrop helps explain why Pfizer has kept buying rather than waiting. It acquired Seagen in 2023 for $43 billion and bought Metsera last year for up to $10 billion, betting on Metsera's GLP-1 drugs as the next wave of growth. The company also generated a profit margin of more than 12% last year, showing that the business still throws off enough cash to fund large moves.
But the gap between the promise and the payoff is still wide. Pfizer has over 100 drug candidates in its pipeline, and some approvals are expected over the next three years, yet the company also knows that sales from several of its top drugs are likely to decline heavily as patents fall away and generic competition bites. The result is a company with scale, cash flow and assets, but one that still has to prove it can replace what is coming off the books.
For now, that is what makes pfe stock hard to own and easy to watch. Investors are not just judging the next quarter. They are judging whether Pfizer can turn a sprawling pipeline and a series of costly acquisitions into revenue fast enough to outrun the losses already on the horizon.
